Published in Cancer Epidemiol Biomarkers Prev on November 01, 2008
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials. JAMA Oncol (2015) 3.64
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol (2012) 1.67
In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertil Steril (2013) 1.59
Menopausal hormone therapy and breast cancer: what is the true size of the increased risk? Br J Cancer (2016) 1.47
Postoophorectomy estrogen use and breast cancer risk. Obstet Gynecol (2012) 1.46
Postmenopausal Female Hormone Use and Estrogen Receptor-Positive and -Negative Breast Cancer in African American Women. J Natl Cancer Inst (2015) 1.44
Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. PLoS One (2012) 1.43
Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study. Am J Epidemiol (2011) 1.22
Reproductive and hormonal factors and lung cancer risk in the NIH-AARP Diet and Health Study cohort. Cancer Epidemiol Biomarkers Prev (2011) 1.20
Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev (2014) 1.17
Prediagnostic Sex Steroid Hormones in Relation to Male Breast Cancer Risk. J Clin Oncol (2015) 1.08
Risk factors for ductal and lobular breast cancer: results from the nurses' health study. Breast Cancer Res (2010) 1.02
Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study. Cancer Epidemiol Biomarkers Prev (2010) 0.97
Hormone-related risk factors and postmenopausal breast cancer among nulliparous versus parous women: An aggregated study. Am J Epidemiol (2011) 0.96
Risk factors for ductal, lobular, and mixed ductal-lobular breast cancer in a screening population. Cancer Epidemiol Biomarkers Prev (2010) 0.95
Mediterranean dietary pattern and risk of breast cancer. PLoS One (2013) 0.91
Lobular breast cancer: incidence and genetic and non-genetic risk factors. Breast Cancer Res (2015) 0.88
Cigarette smoking and postmenopausal breast cancer risk in a prospective cohort. Br J Cancer (2014) 0.88
Long-term relationship of ovulation-stimulating drugs to breast cancer risk. Cancer Epidemiol Biomarkers Prev (2014) 0.88
Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age. Breast Cancer Res Treat (2014) 0.84
Cancers in Australia in 2010 attributable to and prevented by the use of menopausal hormone therapy. Aust N Z J Public Health (2015) 0.84
Can a phenotype for recessive inheritance in breast cancer be defined? Fam Cancer (2010) 0.82
Postmenopausal hormone therapy and breast cancer risk: current status and unanswered questions. Endocrinol Metab Clin North Am (2011) 0.80
Unopposed estrogen and estrogen plus progestin menopausal hormone therapy and lung cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Causes Control (2012) 0.80
Recent declines in breast cancer incidence: mounting evidence that reduced use of menopausal hormones is largely responsible. Breast Cancer Res (2010) 0.79
Cancer incidence attributable to alcohol consumption in Alberta in 2012. CMAJ Open (2016) 0.78
Duration of Adulthood Overweight, Obesity, and Cancer Risk in the Women's Health Initiative: A Longitudinal Study from the United States. PLoS Med (2016) 0.76
Reproducibility of an assay to measure serum progesterone metabolites that may be related to breast cancer risk using liquid chromatography-tandem mass spectrometry. Horm Mol Biol Clin Investig (2015) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Prevalence and trends in obesity among US adults, 1999-2000. JAMA (2002) 33.23
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet (2003) 18.24
Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med (1992) 12.89
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Design and serendipity in establishing a large cohort with wide dietary intake distributions : the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol (2001) 11.17
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med (1995) 11.08
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA (2000) 7.77
National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA (2004) 7.68
Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst (2007) 6.08
Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst (2000) 4.93
Inpatient hysterectomy surveillance in the United States, 2000-2004. Am J Obstet Gynecol (2007) 3.86
Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA (2006) 3.29
Hormone replacement therapy in relation to breast cancer. JAMA (2002) 3.14
Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol (2006) 3.12
Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol (2008) 3.05
Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA (2003) 3.04
Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer (2006) 2.68
Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer (1999) 1.98
Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA (1999) 1.96
Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. Cancer Epidemiol Biomarkers Prev (2008) 1.88
Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer (2000) 1.83
Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol (2002) 1.82
Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer (2003) 1.71
Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer (2002) 1.62
Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev (2002) 1.56
Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer (2004) 1.56
Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer (2004) 1.48
Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med (2006) 1.40
Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med (2005) 1.40
Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control (2003) 1.32
Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer (2004) 1.31
Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res (2006) 1.29
Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort. Int J Cancer (2006) 1.23
Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer (2005) 1.22
Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer (2004) 1.21
Hormone replacement therapy regimens and breast cancer risk(1). Obstet Gynecol (2002) 1.20
Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol (2008) 1.17
Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years. Cancer Epidemiol Biomarkers Prev (2003) 1.13
Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clin Cancer Res (2005) 1.10
Bias in breast cancer analyses due to error in age at menopause. Am J Epidemiol (2000) 1.08
Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial. Hum Reprod (2004) 1.06
Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. Am J Epidemiol (1998) 0.98
Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control (2002) 0.96
Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy. Br J Cancer (2004) 0.95
A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women's health in the Lund area (WHILA) study (Sweden). Cancer Causes Control (2003) 0.94
A prospective study of female hormone use and breast cancer among black women. Arch Intern Med (2006) 0.94
Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada. Cancer Causes Control (2002) 0.87
Combined effect of oral contraceptive use and hormone replacement therapy on breast cancer risk in postmenopausal women. Cancer Causes Control (2003) 0.86
NHLBI stops trial of estrogen plus progestin due to increased breast cancer risk and lack of overall benefit. South Med J (2002) 0.84
Use of oral conjugated estrogen alone and risk of breast cancer. Am J Epidemiol (2006) 0.81
Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med (2006) 16.17
Body-mass index and mortality among 1.46 million white adults. N Engl J Med (2010) 13.34
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Structure of dietary measurement error: results of the OPEN biomarker study. Am J Epidemiol (2003) 8.25
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Using intake biomarkers to evaluate the extent of dietary misreporting in a large sample of adults: the OPEN study. Am J Epidemiol (2003) 7.68
Meat intake and mortality: a prospective study of over half a million people. Arch Intern Med (2009) 6.42
Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst (2007) 6.08
Colonoscopic screening of average-risk women for colorectal neoplasia. N Engl J Med (2005) 5.88
Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern Med (2004) 5.67
Association of coffee drinking with total and cause-specific mortality. N Engl J Med (2012) 5.31
Exercise type and intensity in relation to coronary heart disease in men. JAMA (2002) 4.69
Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA (2002) 4.39
Association between smoking and risk of bladder cancer among men and women. JAMA (2011) 4.31
Fruit and vegetable intake and overall cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst (2010) 3.98
Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst (2006) 3.96
Amount of time spent in sedentary behaviors and cause-specific mortality in US adults. Am J Clin Nutr (2012) 3.95
Performance of a food-frequency questionnaire in the US NIH-AARP (National Institutes of Health-American Association of Retired Persons) Diet and Health Study. Public Health Nutr (2007) 3.88
Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum (2003) 3.84
Dietary fiber intake and mortality in the NIH-AARP diet and health study. Arch Intern Med (2011) 3.77
Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst (2012) 3.69
Mediterranean dietary pattern and prediction of all-cause mortality in a US population: results from the NIH-AARP Diet and Health Study. Arch Intern Med (2007) 3.58
Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst (2007) 3.51
Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer. Am J Epidemiol (2006) 3.41
Postpolypectomy colonoscopy surveillance guidelines: predictive accuracy for advanced adenoma at 4 years. Ann Intern Med (2008) 3.34
Diet, nutrition and the prevention of cancer. Public Health Nutr (2004) 3.28
Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control (2004) 3.10
Body mass and weight change in adults in relation to mortality risk. Am J Epidemiol (2013) 2.87
Meat consumption and prospective weight change in participants of the EPIC-PANACEA study. Am J Clin Nutr (2010) 2.87
Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA (2003) 2.85
Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes. Circulation (2003) 2.80
Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst (2012) 2.77
Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. JAMA (2005) 2.76
Physical activity recommendations and decreased risk of mortality. Arch Intern Med (2007) 2.76
Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol (2008) 2.71
A prospective study of physical activity and incident and fatal prostate cancer. Arch Intern Med (2005) 2.66
A comparison of two dietary instruments for evaluating the fat-breast cancer relationship. Int J Epidemiol (2006) 2.65
Analysis of colorectal cancer occurrence during surveillance colonoscopy in the dietary Polyp Prevention Trial. Gastrointest Endosc (2005) 2.63
Dietary fat and postmenopausal invasive breast cancer in the National Institutes of Health-AARP Diet and Health Study cohort. J Natl Cancer Inst (2007) 2.63
A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology (2008) 2.56
Ongoing colorectal cancer risk despite surveillance colonoscopy: the Polyp Prevention Trial Continued Follow-up Study. Gastrointest Endosc (2009) 2.55
Pooled results from 5 validation studies of dietary self-report instruments using recovery biomarkers for energy and protein intake. Am J Epidemiol (2014) 2.53
Dietary fiber and whole-grain consumption in relation to colorectal cancer in the NIH-AARP Diet and Health Study. Am J Clin Nutr (2007) 2.51
Colorectal cancers soon after colonoscopy: a pooled multicohort analysis. Gut (2013) 2.50
A prospective study of red and processed meat intake in relation to cancer risk. PLoS Med (2007) 2.49
Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer (2004) 2.46
Dealing with dietary measurement error in nutritional cohort studies. J Natl Cancer Inst (2011) 2.43
Formative research of a quick list for an automated self-administered 24-hour dietary recall. J Am Diet Assoc (2007) 2.42
Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med (2008) 2.33
A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol (2007) 2.31
Prospective study of ultraviolet radiation exposure and mortality risk in the United States. Am J Epidemiol (2013) 2.30
Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer (2007) 2.29
Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr (2004) 2.29
Waist circumference and mortality. Am J Epidemiol (2008) 2.26
Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer (2011) 2.23
Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med (2007) 2.23
Lack of effect of a low-fat, high-fruit, -vegetable, and -fiber diet on serum prostate-specific antigen of men without prostate cancer: results from a randomized trial. J Clin Oncol (2002) 2.20
Decline in hepatitis E virus antibody prevalence in southeastern Germany, 1996-2011. Hepatology (2014) 2.18
Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis (2009) 2.17
Consumption of aspartame-containing beverages and incidence of hematopoietic and brain malignancies. Cancer Epidemiol Biomarkers Prev (2006) 2.15
Index-based dietary patterns and risk of incident hepatocellular carcinoma and mortality from chronic liver disease in a prospective study. Hepatology (2014) 2.14
Body mass index and risk of lung cancer among never, former, and current smokers. J Natl Cancer Inst (2012) 2.13
Could exposure assessment problems give us wrong answers to nutrition and cancer questions? J Natl Cancer Inst (2004) 2.12
Psychosocial predictors of energy underreporting in a large doubly labeled water study. Am J Clin Nutr (2004) 2.11
Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers. Breast Cancer Res Treat (2014) 2.10